Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures [Corrigendum]

This article refers to:

Brivaracetam: review of its pharmacology and potential use as adjunctive therapy in patients with partial onset seizures

Mumoli L, Palleria C, Gasparini S, et al. Drug Des Devel Ther. 2015;9:5719–5725.

On page 5722, in Table 1, the notes section is missing; it should read: Klein et al³⁴ data presented as percent reduction in seizure frequency over placebo per 28 days.

On page 5722, left column, line 8, the sentence “The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 9.2% and 20.5% in the BRV 50 and 100 mg/d groups, respectively” should read “The percent reduction over placebo in baseline-adjusted seizure frequency/28 days was 10.2%, 9.2% and 20.5% in the BRV 20, 50 and 100 mg/d groups, respectively”.

On page 5722, right column, line 9, the sentence “Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg” should read “Responder rate was 21.6% for placebo group, 38.9% for BRV 100 mg/d, and 37.8% for BRV 200 mg/d; the percent reduction of partial onset seizures in 28-day frequency over placebo was 22.8% for BRV 100 mg and 23.2% for BRV 200 mg”.

On page 5723, left column, line 22, the sentence “Currently an open-label, multicenter, follow-up study to evaluate the long-term safety and efficacy of BRV is ongoing (BRITE study-NCT01339559)” should read “Currently four open-label, multicenter, follow-up studies to evaluate the long-term safety and efficacy of BRV are ongoing: N01125 (NCT00175916), N01199 (NCT00150800), N01372 (NCT01728077), and N01379 - BRITE (NCT01339559)”.

On page 5724, the first sentence of the Conclusion should read “BRV is a novel AED whose efficacy in partial epilepsies has been studied and established in six randomized controlled trials;^30–35 furthermore, two recent meta-analyses have confirmed significant effects for BRV in patients with refractory partial seizures.^29,43”

In the reference list, page 5725, reference 34 (Klein et al), the link should be: http://www.abstracts2view.com/aan/view.php?nu=AAN15L1_S31.009, which links directly to the abstract text.